Relationship between catechol-O-methyltransferase and phenolsulfotransferase in the metabolism of dopamine in the rat brain.
The relationship between phenolsulfotransferase (PST) and catechol-O-methyltransferase (COMT) in the metabolism of free 3,4-dihydroxyphenylethylamine (DA, dopamine) in the rat brain was studied. In rats not pretreated with a monoamine oxidase (MAO) inhibitor a huge increase of free DA in the brain, following an intraperitoneal injection of L-3,4-dihydroxyphenylalanine (L-DOPA) or an intraventricular injection of free DA, did not lead to any noticeable change in DA sulfate or 3-methoxytyramine (3-MT), which remained undetectable by the present HPLC method. However, in rats previously treated with the MAO inhibitors pargyline or tranylcypromine, the same L-DOPA or free DA treatment resulted in significant increases in both 3-MT and DA sulfate in the hypothalamus, brainstem, and striatum. This response of COMT and PST was not affected by prior treatment of the rats with 6-hydroxydopamine, which suggests that O-methylation and sulfoconjugation occur outside adrenergic neurons not destroyed by the neurotoxin. Inhibition of COMT activity did not lead to any increase in DA sulfate, which showed that despite their common mode of action (both enzymes react preferentially at the same hydroxyl group in the DA molecule), the two enzymes are not competitive. After MAO inhibition there were strong correlations between an increase in DA sulfate and 3-MT on the one hand, and between free DA and 3-MT on the other. Because 3-MT is a marker of central DA release, these data suggest that inhibition of MAO activity not only affects DA metabolism by this enzyme but also influences DA release in the rat brain.
D000818:Animals; D015239:Arylsulfotransferase; D001921:Brain / Q000187:drug effects / Q000201:enzymology*; D002394:Catechol O-Methyltransferase / Q000378:metabolism*; D065098:Catechol O-Methyltransferase Inhibitors; D004298:Dopamine / Q000378:metabolism*; D006892:Hydroxydopamines / Q000494:pharmacology; D007700:Kinetics; D007980:Levodopa / Q000378:metabolism; D008297:Male; D016627:Oxidopamine; D010293:Pargyline / Q000494:pharmacology; D011748:Pyrogallol / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D013466:Sulfurtransferases / Q000378:metabolism*; D014191:Tranylcypromine / Q000494:pharmacology; D014334:Tropolone / Q000494:pharmacology
D065098:Catechol O-Methyltransferase Inhibitors; D006892:Hydroxydopamines; D011748:Pyrogallol; D014191:Tranylcypromine; D007980:Levodopa; D014334:Tropolone; D016627:Oxidopamine; D010293:Pargyline; D002394:Catechol O-Methyltransferase; D013466:Sulfurtransferases; D015239:Arylsulfotransferase; D004298:Dopamine